Question 1

Which peptides are being studied for weight control?

Accepted Answer

The most studied group is incretin analogues. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on GLP-1 and GIP; retatrutide adds a third pathway, glucagon, and is not approved yet, although its phase 3 programme is already well advanced. Other molecules such as cagrilintide are also studied, working through a different, amylin-based mechanism.

Question 2

What is the difference between retatrutide, tirzepatide and semaglutide?

Accepted Answer

They differ in how many pathways they activate and in their status. Semaglutide acts on one pathway, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. Retatrutide is a triple agonist adding glucagon: it is not approved yet, although its manufacturer has reported positive phase 3 results and says it plans an FDA submission in the first quarter of 2027. More pathways does not automatically mean better for a given person.

Question 3

Why can a GLP-1 stop working like it did at first?

Accepted Answer

A plateau, or satiety that feels weaker, does not prove the medicine stopped working. Several factors can contribute at once: energy expenditure falls as weight falls, the perception of satiety habituates, intake and activity context shifts, and clinical or product-side factors exist too. Telling them apart takes follow-up, not assumptions.

Question 4

What should I check if I am not losing weight on a GLP-1?

Accepted Answer

Before concluding anything, look at the trend over time rather than a single week, check whether the product was handled and stored as its labeling states, whether the prescribed regimen has been followed, and what changed in your intake, activity, other medications or medical factors. Treatment changes are decided by whoever provides your clinical follow-up, not a web page or a forum.

Question 5

What are the most common GLP-1 side effects, and which ones need medical attention?

Accepted Answer

The most frequent effects in the approved labels are digestive: nausea, vomiting, diarrhoea, constipation and abdominal pain. They usually show up early and often ease over time. The ones labels flag as reasons to seek care are the severe or persistent ones — especially strong ongoing abdominal pain, vomiting that stops you drinking, or signs of dehydration.

Question 6

Beyond the weight-loss headline, how do semaglutide and tirzepatide actually differ?

Accepted Answer

Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1. That mechanistic difference shows up as somewhat different efficacy and tolerability profiles, and in a direct head-to-head obesity trial tirzepatide produced greater average weight loss. Both share the same family of digestive side effects.

Question 7

Is it true that GLP-1s make you lose muscle as well as fat?

Accepted Answer

Any substantial weight loss takes both fat and lean mass with it; this is not specific to GLP-1s. Trials that measured body composition show part of the lost weight is lean mass, in proportions similar to other forms of rapid weight loss. The open question is what that means for physical function over the long run.

Question 8

What happens to your weight when you stop a GLP-1?

Accepted Answer

Once you stop, the appetite effect goes with it, and withdrawal studies show most people regain a substantial share of the weight they lost. That is why the literature frames obesity as a chronic condition and these drugs as ongoing treatment rather than a finite cycle. Any decision to stop belongs to the prescriber.

Question 9

Do GLP-1s reduce hunger, or do they just slow food leaving the stomach?

Accepted Answer

Both are described. GLP-1 receptor agonists slow gastric emptying, so food stays in the stomach longer, and they also act on brain regions involved in appetite and satiety. The two mechanisms coexist, and how much each contributes varies between molecules and between people.

Question 10

If a trial reports '15% weight loss', is that what I would lose?

Accepted Answer

No. That figure is a group average, and behind it sits a wide distribution: some people land well above it and others well below, including no change. Trials talk about responders and non-responders for exactly this reason. Participants were also selected by inclusion and exclusion criteria that may not match you.

GLP-1 and weight

Affiliate Partners

Peptira

Join the Péptidos Fácil community